Comparable stake leader
Casdin Capital, LLC
SEC ownership of STANDARD BIOTOOLS INC.
Top holders, 13D/G large-stake signals, insider positions, and transaction flow tied to CIK 0001162194.
Disclosed value leader
Casdin Partners Master Fund, L.P.
Comparable rows
50/50
Latest evidence
06 Jun 2026
- Public ticker
- LAB on Nasdaq
- Parsed ownership sources
-
13D/G, 13F, and 3/4/5
Source: Parsed SEC ownership filingsUse: Compare filing families carefully
- Largest SEC-reported holder
-
Casdin Capital, LLC
Ranking: Comparable ownership first, then disclosed value
- Comparable ownership rows
-
50 of 50
Meaning: Rows with safely comparable ownership %
- Latest 13D/G holder
-
Casdin Capital, LLC
Source: Latest parsed Schedule 13D/G stake
- Latest parsed ownership date
-
06 Jun 2026
Freshness: Most recent filing date in this holder set
- Issuer CIK
- 0001162194
- Issuer location
- Boston, MA
Ownership snapshot
CIK-linked ownership evidence from parsed SEC filings.
3 signals
Issuer
Names, identifiers, and filing context for this profile.
2 identity fields
Ownership snapshot
Top shareholders of STANDARD BIOTOOLS INC. (13F + 13D/G + 3/4/5)
Grouped by holder across the latest SEC ownership disclosures. Start with comparable ownership when available, then verify the linked 13F, 13D/G, or 3/4/5 evidence.
Comparable stake leader
Casdin Capital, LLC
Disclosed value leader
Casdin Partners Master Fu...
Comparable rows
50/50
Latest evidence
06 Jun 2026
13D/G
13F
3/4/5
Lead comparable stake: 24%
13D/G row: Casdin Capital, LLC
Showing 1-8 of 50 holder rows.
Quick read
Casdin Capital, LLC leads the comparable SEC ownership view at 24%.
50 of 50 rows have a safely comparable ownership percentage. Use this as a filing-backed starting point, then open the detailed table for source links, reporting role, position value, share count, and filing date.
Open SEC evidence
Opens Casdin Capital, LLC's linked filing trail.
Comparable ownership
Top 5
Casdin Capital, LLC
24%
VIKING GLOBAL INVESTORS LP
15%
MAK Capital Fund LP
6.7%
Casdin Partners Master Fund, L.P.
19%
MAK CAPITAL ONE LLC
6.7%
Ownership % is shown only when SEC disclosures are safely comparable across share classes.
Detailed SEC evidence table Showing 1-8 of 50 holder rows
| Holder | Evidence | Ownership % | Position | 12M Net Δ | As of |
|---|---|---|---|---|---|
| Casdin Capital, LLC |
13D/G
13F
Eli Casdin · Company
|
24%
|
$94,784,236
93,845,778 shares
|
+$407,021 | 06 Jun 2026 |
| VIKING GLOBAL INVESTORS LP |
13D/G
3/4/5
13F
10%+ Owner · Company
|
15%
|
$59,237,682
58,651,170 shares
|
$0 | 06 Jun 2026 |
| MAK Capital Fund LP |
13D/G
|
6.7%
|
$23,293,637
26,172,626 shares
|
+$5,522,504 | 31 Mar 2026 |
| Casdin Partners Master Fund, L.P. |
3/4/5
Director, 10%+ Owner
|
19%
|
$107,795,554
75,001,062 shares
|
+$16,303,018 | 02 Dec 2025 |
| MAK CAPITAL ONE LLC |
13F
Company
|
6.7%
|
$24,060,495
26,172,626 shares
|
— | 31 Mar 2026 |
| BlackRock, Inc. |
13F
Company
|
6.3%
|
$22,758,269
24,756,084 shares
|
— | 31 Mar 2026 |
| Long Focus Capital Management, LLC |
13F
Company
|
4.1%
|
$14,723,252
16,015,721 shares
|
— | 31 Mar 2026 |
| VANGUARD CAPITAL MANAGEMENT LLC |
13F
Company
|
3.3%
|
$11,777,968
12,816,070 shares
|
— | 31 Mar 2026 |
How to read this table
Rows are grouped by holder and ranked first by SEC-reported ownership % when it is safely comparable, then by disclosed holdings value. — indicates unavailable or non-comparable values; "mixed-class rows" means the latest filing spans non-comparable classes.
Forms 3/4/5 flow
Insider trading overview
Net insider flow leans to buying over the last 12 months. Net value: +$16,303,018.
Buys
$16,303,018
Insiders: 1
Sells
$0
Insiders: 0
Net
+$16,303,018
Shares: +12,708,220
Window
Last 12 months
4 rolling buckets
Buy value
Sell value
Shares: 12,708,220
Shares: 0
| Window (months) | Buy shares | Sell shares | Buy value | Sell value | Net value |
|---|---|---|---|---|---|
| 0-3 | 0 | 0 | $0 | $0 | $0 |
| 3-6 | 0 | 0 | $0 | $0 | $0 |
| 6-9 | 11,225,000 | 0 | $14,436,518 | $0 | +$14,436,518 |
| 9-12 | 1,483,220 | 0 | $1,866,500 | $0 | +$1,866,500 |
Reporting owners
Insider holders from Forms 3/4/5
Showing 1-20 of 28 reporting-owner rows connected to STANDARD BIOTOOLS INC.. Open a relationship link for the CIK-to-CIK filing trail.
Rows
28
Largest Forms 3/4/5 holder
Casdin Partners Master Fund, L.P.
Net 12M change
+$16,303,018
Latest report
20 Jun 2026
| Name | Relationship | Holdings Value | Past Year Net Change | Change % | Valuation | Report Date |
|---|---|---|---|---|---|---|
| Casdin Partners Master Fund, L.P. | Director, 10%+ Owner | $107,795,554 | +$16,303,018 | +18% | Mixed | 02 Dec 2025 |
| Eli Casdin | Director, 10%+ Owner | $84,695,853 | Mixed | 18 Jun 2026 | ||
| VIKING GLOBAL INVESTORS LP | 10%+ Owner | $53,225,865 | Mixed | 18 Mar 2024 | ||
| Caligan Partners LP | 10%+ Owner | $34,539,714 | Mixed | 29 Jun 2023 | ||
| Michael Egholm | President & CEO, Director | $12,942,319 | Mixed | 20 May 2026 | ||
| Hanjoon Alex Kim | Chief Financial Officer | $4,510,550 | Mixed | 20 May 2026 | ||
| Sean Mackay | SVP & Chief Business Officer | $2,965,123 | Mixed | 20 Jun 2026 | ||
| Jeffrey G. Black | SVP & Chief Financial Officer | $2,532,070 | Mixed | 20 Aug 2024 | ||
| Casdin Amplify Fund, LP | Director | $1,117,250 | Mixed | 18 Jun 2024 | ||
| Stephen Christopher Linthwaite | President & CEO | $1,004,213 | Mixed | 22 Feb 2022 | ||
| Vikram Jog | Chief Financial Officer | $762,479 | Mixed | 21 Feb 2023 | ||
| Thomas D. Carey | Director | $721,771 | Mixed | 18 Jun 2026 | ||
| Troy Cox | Director | $707,389 | Mixed | 18 Jun 2026 | ||
| Jeremy Steven Davis | SVP Chief Commercial Officer | $667,438 | Mixed | 21 Feb 2023 | ||
| Fenel M. Eloi | Director | $578,317 | Mixed | 18 Jun 2026 | ||
| Frank Witney | Director | $558,923 | Mixed | 18 Jun 2026 | ||
| Nicolas Barthelemy | Director | $518,356 | Mixed | 01 Apr 2022 | ||
| Kathy L. Hibbs | Director | $487,800 | Mixed | 18 Jun 2026 | ||
| Carlos Paya V | Director | $454,505 | Mixed | 14 Jun 2023 | ||
| Gerhard F. Burbach | Director | $405,157 | Mixed | 15 Jun 2022 |
Recent insider transactions for STANDARD BIOTOOLS INC.
Showing up to 300 recent insider transactions from the last 12 months.
| Insider | Symbol | Class | Transaction | % | SEC-reported value | SEC-reported price | Shares | Shares owned | Date | Ownership |
|---|---|---|---|---|---|---|---|---|---|---|
| Sean Mackay | LAB | Common Stock | Award | 49.7% | 500,000 | 1,506,552 | 20 Jun 2026 | Direct | ||
| Thomas D. Carey | LAB | Common Stock | Award | 40.4% | 99,116 | 344,456 | 18 Jun 2026 | Direct | ||
| Thomas D. Carey | LAB | Stock Option (Right to buy) | Award | 263,884 | 263,884 | 18 Jun 2026 | Direct | |||
| Frank Witney | LAB | Common Stock | Award | 47% | 99,116 | 309,978 | 18 Jun 2026 | Direct | ||
| Frank Witney | LAB | Stock Option (Right to buy) | Award | 175,923 | 175,923 | 18 Jun 2026 | Direct | |||
| Eli Casdin | LAB | Common Stock | Award | 3.36% | 99,116 | 3,053,169 | 18 Jun 2026 | Direct | ||
| Eli Casdin | LAB | Stock Option (Right to buy) | Award | 175,923 | 175,923 | 18 Jun 2026 | Direct | |||
| Troy Cox | LAB | Common Stock | Award | 26.3% | 99,116 | 475,702 | 18 Jun 2026 | Direct | ||
| Troy Cox | LAB | Stock Option (Right to buy) | Award | 175,923 | 175,923 | 18 Jun 2026 | Direct | |||
| Fenel M. Eloi | LAB | Common Stock | Award | 42% | 99,116 | 335,299 | 18 Jun 2026 | Direct | ||
| Fenel M. Eloi | LAB | Stock Option (Right to buy) | Award | 175,923 | 175,923 | 18 Jun 2026 | Direct | |||
| Kathy L. Hibbs | LAB | Common Stock | Award | 72% | 99,116 | 236,836 | 18 Jun 2026 | Direct | ||
| Kathy L. Hibbs | LAB | Stock Option (Right to buy) | Award | 175,923 | 175,923 | 18 Jun 2026 | Direct | |||
| Hanjoon Alex Kim | LAB | Common Stock | Tax liability | -0.68% | -18,871 | 2,760,530 | 20 May 2026 | Direct | ||
| Sean Mackay | LAB | Common Stock | Tax liability | -2.49% | -25,729 | 1,006,552 | 20 May 2026 | Direct | ||
| Michael Egholm | LAB | Common Stock | Tax liability | -1.46% | -97,626 | 6,597,956 | 20 May 2026 | Direct | ||
| Michael Egholm | LAB | Common Stock | Tax liability | -1.4% | -95,014 | 6,695,582 | 06 Apr 2026 | Direct | ||
| Michael Egholm | LAB | Common Stock | Options Exercise | 2.98% | 196,513 | 6,790,596 | 06 Apr 2026 | Direct | ||
| Michael Egholm | LAB | Restricted Stock Units | Options Exercise | -100% | -196,513 | 0 | 06 Apr 2026 | Direct | ||
| Hanjoon Alex Kim | LAB | Common Stock | Tax liability | -0.76% | -21,301 | 2,779,401 | 06 Apr 2026 | Direct | ||
| Hanjoon Alex Kim | LAB | Common Stock | Options Exercise | 2.57% | 70,183 | 2,800,702 | 06 Apr 2026 | Direct | ||
| Hanjoon Alex Kim | LAB | Restricted Stock Units | Options Exercise | -100% | -70,183 | 0 | 06 Apr 2026 | Direct | ||
| Michael Egholm | LAB | Common Stock | Award | 18.8% | 1,042,373 | 6,594,083 | 20 Mar 2026 | Direct | ||
| Michael Egholm | LAB | Stock Option (Right to buy) | Award | 2,345,340 | 2,345,340 | 20 Mar 2026 | Direct | |||
| Sean Mackay | LAB | Common Stock | Award | 35.8% | 272,107 | 1,032,281 | 20 Mar 2026 | Direct | ||
| Sean Mackay | LAB | Stock Option (Right to buy) | Award | 612,240 | 612,240 | 20 Mar 2026 | Direct | |||
| Hanjoon Alex Kim | LAB | Common Stock | Award | 13.4% | 323,173 | 2,730,519 | 20 Mar 2026 | Direct | ||
| Hanjoon Alex Kim | LAB | Stock Option (Right to buy) | Award | 727,140 | 727,140 | 20 Mar 2026 | Direct | |||
| Eli Casdin | LAB | Common Stock | Award | 1.83% | 52,991 | 2,954,053 | 26 Feb 2026 | Direct | ||
| Troy Cox | LAB | Common Stock | Award | 17.9% | 57,264 | 376,586 | 26 Feb 2026 | Direct | ||
| Thomas D. Carey | LAB | Common Stock | Award | 26.4% | 51,282 | 245,340 | 26 Feb 2026 | Direct | ||
| Michael Egholm | LAB | Common Stock | Tax liability | -1.18% | -66,127 | 5,551,710 | 23 Feb 2026 | Direct | ||
| Sean Mackay | LAB | Common Stock | Tax liability | -2.52% | -19,661 | 760,174 | 23 Feb 2026 | Direct | ||
| Hanjoon Alex Kim | LAB | Common Stock | Tax liability | -0.53% | -12,740 | 2,407,346 | 23 Feb 2026 | Direct | ||
| Casdin Partners Master Fund, L.P. | LAB | Common Stock, $0.001 par value per share | Purchase | 0.21% | $217,020 | $1.45 | 150,000 | 72,100,000 | 04 Dec 2025 | See footnote |
| Casdin Partners Master Fund, L.P. | LAB | Common Stock, $0.001 par value per share | Purchase | 0.1% | $108,038 | $1.44 | 75,000 | 71,950,000 | 03 Dec 2025 | See footnote |
| Casdin Partners Master Fund, L.P. | LAB | Common Stock, $0.001 par value per share | Purchase | 0.17% | $177,512 | $1.42 | 125,000 | 71,875,000 | 02 Dec 2025 | See footnote |
| Casdin Partners Master Fund, L.P. | LAB | Common Stock, $0.001 par value per share | Purchase | 11.8% | $9,838,405 | $1.30 | 7,550,000 | 71,750,000 | 25 Nov 2025 | See footnote |
| Casdin Partners Master Fund, L.P. | LAB | Common Stock, $0.001 par value per share | Purchase | 0.23% | $214,875 | $1.43 | 150,000 | 64,200,000 | 24 Nov 2025 | See footnote |
| Michael Egholm | LAB | Common Stock | Tax liability | -1.12% | -63,529 | 5,617,837 | 20 Nov 2025 | Direct | ||
| Hanjoon Alex Kim | LAB | Common Stock | Tax liability | -0.52% | -12,739 | 2,415,086 | 20 Nov 2025 | Direct | ||
| Sean Mackay | LAB | Common Stock | Tax liability | -2.46% | -19,661 | 779,835 | 20 Nov 2025 | Direct | ||
| Casdin Partners Master Fund, L.P. | LAB | Common Stock, $0.001 par value per share | Purchase | 0.71% | $586,260 | $1.30 | 450,000 | 64,050,000 | 20 Nov 2025 | See footnote |
| Casdin Partners Master Fund, L.P. | LAB | Common Stock, $0.001 par value per share | Purchase | 0.55% | $448,910 | $1.28 | 350,000 | 63,600,000 | 19 Nov 2025 | See footnote |
| Casdin Partners Master Fund, L.P. | LAB | Common Stock, $0.001 par value per share | Purchase | 0.44% | $339,405 | $1.23 | 275,000 | 63,250,000 | 18 Nov 2025 | See footnote |
| Casdin Partners Master Fund, L.P. | LAB | Common Stock, $0.001 par value per share | Purchase | 0.36% | $275,580 | $1.22 | 225,000 | 62,975,000 | 17 Nov 2025 | See footnote |
| Casdin Partners Master Fund, L.P. | LAB | Common Stock, $0.001 par value per share | Purchase | 0.4% | $309,800 | $1.24 | 250,000 | 62,750,000 | 14 Nov 2025 | See footnote |
| Casdin Partners Master Fund, L.P. | LAB | Common Stock, $0.001 par value per share | Purchase | 0.73% | $541,395 | $1.20 | 450,000 | 62,500,000 | 13 Nov 2025 | See footnote |
| Casdin Partners Master Fund, L.P. | LAB | Common Stock, $0.001 par value per share | Purchase | 0.61% | $445,838 | $1.19 | 375,000 | 62,050,000 | 12 Nov 2025 | See Footnote |
| Casdin Partners Master Fund, L.P. | LAB | Common Stock, $0.001 par value per share | Purchase | 0.49% | $358,800 | $1.20 | 300,000 | 61,675,000 | 11 Nov 2025 | See Footnote |
* marks a reported price that did not pass the local price check.